<DOC>
	<DOCNO>NCT01493596</DOCNO>
	<brief_summary>Primary Objective : • To evaluate safety tolerability ascend single oral dos CPP-115 Secondary Objective : • To determine pharmacokinetic profile CPP-115 follow administration ascend single oral dos</brief_summary>
	<brief_title>A Safety , Tolerability Pharmacokinetic Study CPP-115</brief_title>
	<detailed_description />
	<criteria>1 . Willing able give write informed consent comply study procedures requirement . 2 . Males , age 18 65 year . 3 . Body Mass Index 19 32 kg/m2 . 4 . Normal systolic blood pressure ( BP [ 90140 mmHg ] ) , diastolic BP ( 50 90 mmHg ) heart rate ( HR [ rest HR 4090 beat per minute ( bpm ) ] ) . 5 . Willing able abstain drug , alcohol , tobacco use study participation . 1 . Medical history and/or finding physical examination indicate presence clinically significant illness . 2 . Clinically significant abnormality vital sign clinical laboratory result ( include hematology , chemistry , urinalysis ) . 3 . Presence recent history ( within 28 day prior Screening ) active clinically significant ( judged Investigator ) gastrointestinal , renal , cardiovascular , hepatic , metabolic , allergic , dermatologic , hematologic , pulmonary , neurological psychiatric illness disorder . 4 . History stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug . 5 . Clinically significant ECG abnormality include QTc ≥ 450 msec . 6 . Use tobaccocontaining nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine lozenge , nicotine gum ) within 6 month prior Screening . 7 . Use prescription , illegal , investigational drug within 28 day prior Day 1 . 8 . Use overthecounter ( OTC ) drug , include vitamin , mineral , dietary/herbal supplement , grapefruit grapefruit juice within 14 day prior Day 1 . 9 . Use alcohol , caffeine , poppy seedcontaining food beverage within 72 hour prior Day 1 . 10 . History recent ( within 6 month ) drug alcohol abuse , define DSM IV ( Diagnostic Statistical Manual Mental Disorders , Fourth Edition ) . 11 . Positive urine drug screen , urine cotinine test , alcohol breath test Screening checkin clinical study unit ( CSU ) . Subjects result believe false positive allow screen result retested specialized laboratory . 12 . Positive serology surface antigen Hepatitis B ( HBsAg ) , Hepatitis C ( anti HCV ) , human immunodeficiency virus ( HIV ) antibody screen . 13 . Donation blood plasma blood bank clinical study ( except study screen ) within 28 day prior Day 1 . 14 . Receipt blood product within 2 month prior Screening . 15 . Any condition reason , opinion Investigator , would render subject unsuitable clinical study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
</DOC>